Searched for
DRUGMAKER BAYER
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...- Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
- US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claimsA US judge has dismissed Bayer's plea to halt Johnson & Johnson's advertising for its prostate cancer drug Erleada. Bayer alleged false cla...
- Amazon launches AI research tool to speed early-stage drug discoveryAmazon Web Services has launched Amazon Bio Discovery, an AI tool to accelerate drug discovery. Scientists can now generate and evaluate po...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Natco’s compulsory licence for selling generic copies of Bayer’s cancer drug Nexavar upheld by IpabThe Indian patents appeals board had last year dismissed Bayer’s petition seeking a stay on the “compulsory licence” issued to Natco.
- Pfizer to appeal India decision to revoke cancer drug patentPfizer Ltd, the India unit of US drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug...
- IPAB dismisses Bayer's stay plea in Nexavar caseIPAB of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmake...
- Bayer demands withdrawal of Natco Pharma's compulsory licenceIn March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's pr...
- China beats India in race to attract global pharma companiesIn the past two years, cos such as GlaxoSmithkline, Novartis and Astra Zeneca have turned focus to China, promising investment worth billio...
- Bayer AG expects India sales to double by 2015Bayer AG said it expects sales in India to double by 2015 and targets more than 60% increase in revenue from entire Asia during the period
- Non-compliance with disclosure norms on patents may bring trouble for pharma companiesSeveral global drugmakers, including Pfizer, Roche and Bayer, have not met full mandatory disclosures of their patented medicines in India,...
- Natco may seek compulsory licence for Bayer's cancer drugNatco Pharma plans to seek a compulsory licence to make Bayer AG's Nexavar in India, invoking a provision in local laws that allows generic...
- SC quashes Bayer petition to block Cipla generic drugThe country’s top judicial authority has dismissed German pharmaceutical firm Bayer AG’s attempt to block Indian drug regulator from allowi...
- Cipla makes cancer drug cheaperCipla has launched a copycat version of German pharma company Bayer’s cancer medicine Nexavar at one-tenth the price.
- Bayer drags Cipla to court over patentGerman drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based compa...
- SC rejects Bayer’s plea to stay Cipla’s cancer cloneThe Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- No interim stay on Cipla’s Nexavar cloneThe Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- HC allows CPAA to join Bayer-Cipla caseThe Delhi High Court (HC) has allowed cancer patient group Cancer Patients Aid Association (CPAA) to join the Bayer AG and Cipla case.
- Bayer becomes largest supplier of resins and filmsBayer AG, Germany's largest drugmaker, completed its acquisition of Taiwan Ure-Tech Group, making Bayer the world's largest supplier of res...
Load More
